Conflict probe turns to Stanford

Written byBob Grant

| 2 min read

The irascible conflict of interest hunter, linkurl:Senator Charles Grassley;http://www.the-scientist.com/blog/display/54561/ (R-IA), has set his sights on a Stanford University psychiatrist who's running a federally funded clinical trial on a drug made by the same company in which he owns millions of dollars in stock. The psychiatrist is linkurl:Alan Schatzberg,;http://med.stanford.edu/profiles/Alan_Schatzberg and he is the chair of the psychiatry department at Stanford's School of Medicine. Schatzberg owns $6 million of stock in linkurl:Corcept Therapeutics,;http://www.corcept.com/ according to stories in linkurl:__Science__;http://sciencenow.sciencemag.org/cgi/content/full/2008/624/1 and in the linkurl:__San Jose Mercury News__.;http://www.mercurynews.com/lifeandstyleheadlines/ci_9689122?nclick_check=1 The company produces mifepristone, an abortion drug (also known as linkurl:RU-486);http://www.the-scientist.com/article/display/10905/ that is being tested as a depression treatment. Schatzberg is the lead investigator on an NIH-funded study of mifepristone taking place at Stanford, though he is not directly involved in recruiting study subjects or testing patients. Schatzberg and Stanford have attracted Grassley's withering gaze because the Senator, who is the ranking member of the Senate's Committee on Finance, says that the university did not require the researcher to disclose the fact that he owned such a sizable chunk of Corcept Therapeutics stock. Stanford's conflict policies do require investigators to disclose financial conflicts valuing more than $100,000, but for some reason Schatzberg's holdings slipped through the university policy's cracks. "Obviously, $6 million is a dramatically higher number than $100,000 and I am concerned that Stanford may not have been able to adequately monitor the degree of Dr. Schatzberg's conflicts of interest with its current disclosure policies," Grassley wrote in a June 23 linkurl:letter;http://frwebgate1.access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=425632504759+0+1+0&WAISaction=retrieve published in the __Congressional Record__. In the letter, Grassley also outlines instances where Schatzberg received pharmaceutical company payments that he failed to report to Stanford, including an unreported $22,000 Schatzberg got from Johnson and Johnson in 2002. Grassley provides a list of such discrepancies in his letter to Stanford and writes: "The lack of consistency between what Dr. Schatzberg reported to Stanford and what several drug companies reported to me seems to follow a pattern of behavior. More specifically, I have uncovered inconsistent reporting patterns at the University of Cincinnati, and at Harvard University and Mass General Hospital," referring to conflicts among researchers at other institutions Grassley has investigated. A 2006 linkurl:story;http://daily.stanford.edu/article/2006/7/13/potentialConflictsForTrustees in __The Stanford Daily__ stated that Schatzberg co-founded Corcept Therapeutics, and that the University granted the company an exclusive license to develop his patented technologies into FDA-approved treatments. Allegations of conflict between Schatzberg's scientific and financial goals were first raised, according to __The Stanford Daily__ story, when two research psychiatrists at the annual meeting of the American College of Neuropsychopharmacology publicly stated that RU-486's effectiveness in treating depression was questionable and said that Schatzberg's science was compromised by his ties to Corcept Therapeutics.

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

Conflict probe turns to Stanford

The Scientist ARCHIVES

Become a Member of

Related Topics

Meet the Author

Bob Grant

Related Research Resources

Why Do We Feel Butterflies in the Stomach?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Research Roundtable: The Evolving World of Spatial Biology

Exploring the State of the Art in Gene Editing Techniques

Simplifying Early Alzheimer’s Disease Diagnosis with Blood Testing

Products

Product News

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

EVIDENT's New FLUOVIEW FV5000 Redefines the Boundaries of Confocal and Multiphoton Imaging

EVIDENT Launches Sixth Annual Image of the Year Contest

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research